>>> Revance Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. It develops RT001, a topical gel formulation of botulinum toxin type A that is in Phase III development program for the treatment of crow?s feet lines in North America; and in Phase II clinical trial for the treatment of primary axillary hyperhidrosis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is in a Phase II clinical trial for the treatment of glabellar lines and cervical dystonia. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California. <<<
